Drugs are never been used after they met their expiry dates. But according to scientists some drugs product which may be over-the-counter drugs or from other category may be used even after the their expiration. In this context U.S. Military performed a million dollar research on the efficacy of the drug products with expiry date all about 27 years ago on more than 100 products available in the market at that time. And a the research succeeded scientists were surprised with the results which proves that 90% of the drugs can be used even after the expiry date with the same efficacy.
So, Again the question was that why the companies mention the expiry dates if drug can withstand their efficacy for such a long time.
whatever will be the reason but research over this concept is a bit under controversy as it is a multi billion market which growing yeay after year and also is related with the human welfare
Wednesday 12 December 2012
Tuesday 24 July 2012
Tudorza Pressair (aclidinium bromide): Approved by US FDA
Tudorza pressair i.e. aclidinium bromide recently approved by the US FDA which is very good bronchodilator long term management of the brochospasm which generally occurs due to bronchospasm (narrowing of the airways in the lung) which normally associated with COPD (chronic obstructive pulmonary disease), including chronic bronchitis and emphysema.
In case of COPD, it makes it difficult to breathe.
There are two main forms of COPD:
COPD is caused by noxious particles or gas, most commonly from tobacco smoking, which triggers an abnormal inflammatory response in the lungs.
“COPD is a serious disease that gets worse over time,” said Curtis Rosebraugh, M.D., M.P.H., director of the Office of Drug Evaluation II in FDA’s Center for Drug Evaluation and Research.
“The availability of long-term maintenance drugs for COPD provides additional treatment options for the millions of people who suffer with this debilitating disease.”
The safety and efficacy of Tudorza Pressair were demonstrated in three randomized, placebo-controlled confirmatory clinical trials that included 1,276 patients ages 40 and older with a clinical diagnosis of COPD. Those treated had a smoking history of at least one pack a day for 10 years.
Source: US FDA
There are two main forms of COPD:
- Chronic bronchitis, which involves a long-term cough with mucus
- Emphysema, which involves destruction of the lungs over time
COPD is caused by noxious particles or gas, most commonly from tobacco smoking, which triggers an abnormal inflammatory response in the lungs.
“COPD is a serious disease that gets worse over time,” said Curtis Rosebraugh, M.D., M.P.H., director of the Office of Drug Evaluation II in FDA’s Center for Drug Evaluation and Research.
“The availability of long-term maintenance drugs for COPD provides additional treatment options for the millions of people who suffer with this debilitating disease.”
The safety and efficacy of Tudorza Pressair were demonstrated in three randomized, placebo-controlled confirmatory clinical trials that included 1,276 patients ages 40 and older with a clinical diagnosis of COPD. Those treated had a smoking history of at least one pack a day for 10 years.
- Tudorza Pressair may cause serious side effects, including paradoxical bronchospasm, new or worsened increased pressure in the eyes (acute narrow-angle glaucoma), or new or worsened urinary retention. Tudorza Pressair should not be used as a rescue therapy to treat sudden breathing problems (acute bronchospasm) and is not recommended for people younger than 18 years.
- Side effects reported by patients using Tudorza Pressair include headache, inflammation of the nasal passage (nasopharyngitis), and cough.
Source: US FDA
Wednesday 11 July 2012
Lipitor : Best selling drug in Pharmaceutical History
Lipitor, a drug by Pfizer boomed up the sale of the pfizer in past years of its patent period and recorded as best selling drug in history of pharmaceutical industry. Lipitor is a brand name of drug Atorvastatin calcium developed and patented by pfizer and patent expired last year in november 2011. It is called as The Blockbuster Drug due to its sales profile. Its sales of more than $10 billion worldwide last year. Also, overall business of this particular drug was accounted as high as more than $130 billion. Lipitor, is a statin class of drug helps to reduce High Cholestrol level in blood, thus, administered in case of stroke, heart attack and other cholestrol related problems.
As patent got expired last year in November 2011, after that the field was opened for the other biggies of pharmaceutical industries to manufacture the generic form of lipitor (Atorvastatin calcium) and promote the sale of cheap products of the atorvastatin as compared to lipitor price in past.
Now, an Indian MNC launched its own generic product of atorvastatin as Atorvastatin Calcium is Ranbaxy Laboratory in December 2011 at a very reseonable price. Also, other companies like Cipla and TEVA also launched their Atorvastatin calcium formulations in UK market and around the world at very reasonable price. So, finally it was a good farewell for a best selling blockbuster drug which made and broke many records with respect to the money and all. So, overall, it is a good news for the patients with low finance backgroud that they can now consume a best statin drug of all time at a reasonable cost.
Tuesday 10 July 2012
Patent Expired Drugs in 2012 and 2013
In current year, about 25 drugs are there whose patent going to be expired in United kingdom.
the drugs whose patent expired or yet to be expired in 2012 are listed below as:
other drugs whose patents will be expire in year 2013 are:
So, these are drugs drugs whose patents were expired or will be expire in future. So, these drugs will be good for those who like to research on new drugs like Pharmacy scholars.
the drugs whose patent expired or yet to be expired in 2012 are listed below as:
Patents expiring in 2012
Approved Name
|
BNF
|
UK-patent expiry
|
|
Atorvastatin ¨
|
2.12
|
06/05/2012
|
|
Bemiparin«
|
2.8.1
|
21/07/2012
|
|
Candesartan«
|
2.5.5.2
|
28/04/2012
|
|
Cidofovir
|
5.3.2.2
|
22/04/2012
|
|
Desogestrel «
|
7.3.2.1
|
11/12/2012
|
|
Dipyridamole + Aspirin «
|
2.9
|
08/07/2012
|
|
Donepezil HCl «
|
4.11
|
13/02/2012
|
|
Doripenem «
|
5.1.2.2
|
17/08/2012
|
|
Entacapone «
|
4.9.1
|
26/11/2012
|
|
Eprosartan mesylate «
|
2.5.5.2
|
14/04/2012
|
|
Eptifibatide «
|
2.9
|
26/02/2012
|
|
Galantamine «
|
4.11
|
15/01/2012
|
|
Indinavir
|
5.3.1
|
01/11/2012
|
|
Irbesartan «
|
2.5.5.2
|
14/08/2012
|
|
Latanoprost ¨
|
11.6
|
17/01/2012
|
|
Lepirudin «
|
2.8.1
|
12/03/2012
|
|
Mometasone furoate «
|
3.2
|
18/02/2012
|
|
Naratriptan «
|
4.7.4
|
09/03/2012
|
|
Quetiapine fumarate «
|
4.2.1
|
23/03/2012
|
including XL formulation
|
Rabeprazole «
|
1.3.5
|
12/11/2012
|
|
Ramipril + Felodipine «
|
2.5.5.1
|
18/09/2012
|
|
Rivastigmine hydrogen tartrate«
|
4.11
|
30/07/2012
|
|
Tolcapone «
|
4.9.1
|
24/02/2012
|
|
Tolterodine tartrate «
|
7.4.2
|
04/09/2012
|
|
Zolmitriptan«
|
4.7.4
|
06/03/2012
|
« drugs with SPC extension
¨ drugs
with SPC paediatric extension
Patents expiring in 2013
Approved Name
|
BNF
|
UK-patent expiry
|
Basiliximab «
|
8.2.2
|
06/04/2013
|
Capecitabine «
|
8.1.3
|
09/06/2013
|
Clopidogrel hydrogen sulphate¨
|
2.9
|
15/08/2013
|
Dorzolamide + Timolol «
|
11.6
|
05/03/2013
|
Efavirenz «
|
5.3.1
|
19/11/2013
|
Etonogestrel «
|
7.3.1
|
06/07/2013
|
Fosphenytoin sodium «
|
4.8.2
|
03/02/2013
|
Hydroxyethyl starch «
|
9.2.2.2
|
19/11/2013
|
Irbesartan +hydrochlorothiazide«
|
2.5.5.2
|
14/10/2013
|
Montelukast sodium ¨
|
3.3.2
|
24/02/2013
|
Nelarabine «
|
8.1.3
|
26/05/2013
|
Nevirapine ¨
|
5.3.1
|
22/06/2013
|
Raloxifene HCl
|
6.4.1.1
|
04/08/2013
|
Rituximab «
|
8.2.3
|
21/11/2013
|
Rizatriptan ¨
|
4.7.4
|
10/08/2013
|
Salmeterol xinafoate+ Fluticasone propionate «
|
3.2
|
06/09/2013
|
Sildenafil «
|
2.5.1/7.4.5
|
21/06/2013
|
Telmisartan «
|
2.5.5.2
|
10/12/2013
|
Tirofiban HCl «
|
2.9
|
27/05/2013
|
Zidovudine + Lamivudine «
|
5.3.1
|
17/03/2013
|
Zoledronic acid ¨
|
6.6.2
|
15/05/2013
|
« drugs with SPC extension
¨ drugs
with SPC paediatric extension
Subscribe to:
Posts (Atom)